{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:11:24Z","timestamp":1783678284606,"version":"3.55.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We aimed to improve prognostic predictors in patients with transplant-ineligible multiple myeloma (TIE-MM) by combining baseline circulating clonal tumor cells (CTCs) and positron emission tomography\/computed tomography (PET\/CT) findings. The factors associated with prognosis were retrospectively investigated in 126 patients with TIE-MM who underwent CTC quantification by multiparameter flow cytometry and PET\/CT at the initial presentation. The total lesion glycolysis (TLG) level was calculated using the Metavol software. The median percentage of CTC was 0.06% (range, 0%-4.82%), and 54 patients (42.9%) demonstrated high CTC levels. High CTC levels were associated with significantly poorer progression-free survival (PFS, 2-year 43.4% vs 68.1%; P\u00a0&amp;lt; .001) and overall survival (OS, 5-year 39.0% vs 68.3%; P\u00a0&amp;lt; .001). Similarly, high TLG levels significantly worsened the PFS (2-year, 41.2% vs 67.6%; P\u00a0= .038) and OS (5-year, 37.7% vs 63.1%; P\u00a0= .019). The multivariate analyses showed that Revised International Staging System (R-ISS) III, high CTC and TLG levels, and complete response were significant prognostic factors for PFS and OS. A novel predictive model was constructed using CTCs, TLG, and R-ISS III. The patients were stratified into 3 groups according to the number of risk factors, revealing an extremely high-risk group with a 2-year PFS of 0% and a 5-year OS of 20%. Patients without any high-risk features had better prognosis, with a 2-year PFS of 78.6% and a 5-year OS of 79.5%. The combination of CTCs and volumetric assessment of PET\/CT at diagnosis augments the existing stratification systems and may pave the way for a risk-adapted treatment approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011890","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T16:37:10Z","timestamp":1703695030000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of baseline circulating tumor cells integrated with PET\/CT findings in transplant-ineligible multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-4616","authenticated-orcid":false,"given":"Daisuke","family":"Ikeda","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3346","authenticated-orcid":false,"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-4647","authenticated-orcid":false,"given":"Mitsuaki","family":"Oura","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uehara","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-9046","authenticated-orcid":false,"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Machida","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-9865","authenticated-orcid":false,"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"2024010913591474000_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2024010913591474000_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-021-00524-1","article-title":"Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect((R)) MM Registry","volume":"11","author":"Lee","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"2024010913591474000_bib3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024010913591474000_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3324\/haematol.2016.145078","article-title":"Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma","volume":"102","author":"Kastritis","year":"2017","journal-title":"Haematologica"},{"issue":"24","key":"2024010913591474000_bib5","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","article-title":"Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance","volume":"23","author":"Kumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024010913591474000_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2024010913591474000_bib7","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2024010913591474000_bib8","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J"},{"issue":"8","key":"2024010913591474000_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3324\/haematol.2017.166629","article-title":"Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation","volume":"102","author":"Chakraborty","year":"2017","journal-title":"Haematologica"},{"issue":"27","key":"2024010913591474000_bib10","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024010913591474000_bib11","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024010913591474000_bib12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024010913591474000_bib13","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.22.01040","article-title":"Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time?","volume":"40","author":"Chakraborty","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024010913591474000_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/16078454.2021.1948208","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021","journal-title":"Hematology"},{"issue":"3","key":"2024010913591474000_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.25709","article-title":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells","volume":"95","author":"Gonsalves","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2024010913591474000_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","article-title":"The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma","volume":"193","author":"Galieni","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2024010913591474000_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.16633","article-title":"Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography\/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice","volume":"191","author":"Terao","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2024010913591474000_bib18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024010913591474000_bib19","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"2024010913591474000_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024010913591474000_bib21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024010913591474000_bib22","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024010913591474000_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2024010913591474000_bib24","doi-asserted-by":"crossref","first-page":"14956","DOI":"10.1038\/s41598-021-94191-8","article-title":"Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria","volume":"11","author":"Narita","year":"2021","journal-title":"Sci Rep"},{"issue":"23","key":"2024010913591474000_bib25","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024010913591474000_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","article-title":"Low hexokinase-2 expression-associated false-negative (18)F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024010913591474000_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2024010913591474000_bib28","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024010913591474000_bib29","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024010913591474000_bib30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00259-019-4275-5","article-title":"Pretreatment (18)F-FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2024010913591474000_bib31","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2024010913591474000_bib32","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1038\/s41598-021-89761-9","article-title":"Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods","volume":"11","author":"Yoroidaka","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"2024010913591474000_bib33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of (18)F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024010913591474000_bib34","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1007\/s00330-021-07687-2","article-title":"Total diffusion volume in MRI vs. total lesion glycolysis in PET\/CT for tumor volume evaluation of multiple myeloma","volume":"31","author":"Terao","year":"2021","journal-title":"Eur Radiol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/37\/2180574\/blooda_adv-2023-011890-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/37\/2180574\/blooda_adv-2023-011890-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:00:22Z","timestamp":1704808822000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/37\/498717\/Analysis-of-baseline-circulating-tumor-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011890","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}